


Ask a doctor about a prescription for VIREAD 245 mg FILM-COATED TABLETS
Package Leaflet: Information for the Patient
Viread 245 mg Film-Coated Tablets
Tenofovir Disoproxil
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the Pack
If Viread has been prescribed to your child, note that all the information in this leaflet is intended for your child (in this case, read “your child” instead of “you”).
Viread contains the active substance tenofovir disoproxil. This active substance is an antiretroviral or antiviral medicine used to treat HIV or HBV infection or both. Tenofovir is a nucleotide reverse transcriptase inhibitor, commonly known as NtRTI, which works by interfering with the normal function of an enzyme (in the case of HIV, reverse transcriptase, and in hepatitis B, DNA polymerase) that is essential for the viruses to reproduce. For the treatment of HIV infection, Viread must always be used in combination with other medicines.
Viread 245 mg film-coated tablets are a medicine used to treat HIV (Human Immunodeficiency Virus) infection.The tablets are suitable for:
Viread 245 mg film-coated tablets are also a medicine used to treat chronic hepatitis B, an infection caused by the hepatitis B virus (HBV).The tablets are suitable for:
You do not need to have HIV to be treated with Viread for HBV.
This medicine is not a cure for HIV infection. While your child is taking Viread, they may still develop infections or other illnesses associated with HIV infection. They may also continue to transmit HIV or HBV to others. Therefore, it is important that they take precautions to avoid infecting others.
Do not take Viread
Warnings and precautions
Talk to your doctor or pharmacist before you start taking Viread.
Viread is not normally taken with other medicines that can damage your kidneys (see Taking Viread with other medicines). If this is unavoidable, your doctor will monitor your kidney function once a week.
Bone problems (sometimes resulting in fractures) may also occur due to damage to the kidney tubule cells (see section 4, Possible side effects).
In addition to opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you have started taking medicines for the treatment of your HIV infection.
Autoimmune disorders may occur many months after starting treatment. If you observe any symptoms of infection or other symptoms such as muscle weakness, weakness starting in the hands and feet and moving up towards the trunk of the body, palpitations, tremor, or hyperactivity, tell your doctor immediately to receive the necessary treatment.
Children and adolescents
Viread 245 mg film-coated tablets are suitablefor:
Viread 245 mg film-coated tablets are notsuitable for the following groups:
For dosing information, see section 3, How to take Viread.
Other medicines and Viread
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
These include:
Taking Viread with food and drinks
Take Viread with food(for example, a meal or snack).
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
Viread may cause dizziness. If you feel dizzy while taking Viread, do not drive or ride a bicycleor use tools or machines.
Viread contains lactose
Tell your doctor before taking Viread.If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
Always take this medicine exactly as your doctor or pharmacist has told you.If you are not sure, check with your doctor or pharmacist.
The recommended dose is:
If you have difficulty swallowing, you can use the tip of a spoon to crush the tablet. Then, mix the powder with approximately 100 ml of water (half a glass), orange juice, or grape juice, and drink it immediately.
Consult the package leaflets of your other antiretrovirals to find out how to take these medicines.
If you take more Viread than you should
If you have accidentally taken too many Viread tablets, you may have a higher risk of experiencing possible side effects with this medicine (see section 4, Possible side effects). Talk to your doctor or go to the nearest emergency department. Take the pack of tablets with you so that you can easily describe what you have taken.
If you forget to take Viread
It is important that you do not miss a dose of Viread. If you miss a dose, determine how long ago you should have taken it.
If you vomit within 1 hour of taking Viread,take another tablet. You do not need to take another tablet if you vomit more than 1 hour after taking Viread.
If you stop taking Viread
Do not stop taking Viread without talking to your doctor. Stopping treatment with Viread may reduce the effectiveness of the treatment recommended by your doctor.
If you have hepatitis B or HIV and hepatitis B (co-infection),it is very important that you do not stop your treatment with Viread without first talking to your doctor. After stopping treatment with Viread, some patients have had blood tests or symptoms indicating that their hepatitis had worsened. You may need to have blood tests for several months after stopping treatment. In patients with advanced liver disease or cirrhosis, it is not recommended to stop treatment, as this may lead to worsening of hepatitis.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
During HIV treatment, there may be an increase in weight and glucose and lipid levels in the blood. This may be partly related to the recovery of health and lifestyle, and in the case of blood lipids, sometimes with HIV medications themselves. Your doctor will monitor these changes.
Like all medications, this medication can cause adverse effects, although not all people experience them.
Possible Serious Adverse Effects: Report to Your Doctor Immediately
Other Possible Serious Adverse Effects
The following adverse effects are uncommon(may affect up to 1 in 100 patients):
The following adverse effects are rare (may affect up to 1 in 1,000 patients):
More Frequent Adverse Effects
The following adverse effects are very common(may affect at least 10 out of 100 patients):
Lab tests may also show:
Other Possible Adverse Effects
The following adverse effects are common(may affect up to 10 out of 100 patients):
Lab tests may also show:
The following adverse effects are uncommon(may affect up to 1 in 100 patients):
Lab tests may also show:
Muscle rupture, bone weakening (with bone pain and sometimes resulting in fractures), muscle pain, muscle weakness, and decreased blood potassium or phosphate levels may occur due to kidney tubule cell damage.
The following adverse effects are rare(may affect up to 1 in 1,000 patients):
Reporting Adverse Effects
If you experience any adverse effects, consult your doctor or pharmacist,even if they are possible adverse effects not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can help provide more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date shown on the bottle and carton after EXP. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medications should not be disposed of through wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Viread Composition
Product Appearance and Package Contents
Viread 245 mg film-coated tablets are light blue, almond-shaped tablets, 16.8 mm x 10.3 mm in size, marked with "GILEAD" and "4331" on one side and "300" on the other. Viread is available in bottles containing 30 tablets. Each bottle contains a silica gel desiccant that should be kept inside the bottle to protect the tablets. The silica gel desiccant is contained in a separate pouch or container and should not be swallowed.
This medication is available in packages of 1 bottle of 30 film-coated tablets and 3 bottles of 30 film-coated tablets. Not all package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Gilead Sciences Ireland UC
Carrigtohill
County Cork, T45 DP77
Ireland
Manufacturer:
Takeda GmbH
Lehnitzstrasse 70-98
D-16515 Oranienburg
Germany
or
Gilead Sciences Ireland UC
IDA Business & Technology Park
Carrigtohill
County Cork
Ireland
You can request more information about this medication from the local representative of the Marketing Authorization Holder:
België/Belgique/Belgien Gilead Sciences Belgium SPRL-BVBA Tel: + 32 (0) 24 01 35 50 | Lietuva Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 |
?????? Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 | Luxembourg/Luxemburg Gilead Sciences Belgium SPRL-BVBA Tel: + 32 (0) 24 01 35 50 |
Ceská republika Gilead Sciences s.r.o. Tel: + 420 910 871 986 | Magyarország Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Danmark Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1849 | Malta Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Deutschland Gilead Sciences GmbH Tel: + 49 (0) 89 899890-0 | Nederland Gilead Sciences Netherlands B.V. Tel: + 31 (0) 20 718 36 98 |
Eesti Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 | Norge Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1849 |
Ελλ?δα Gilead Sciences Ελλ?ς Μ.ΕΠΕ. Τηλ: + 30 210 8930 100 | Österreich Gilead Sciences GesmbH Tel: + 43 1 260 830 |
España Gilead Sciences, S.L. Tel: + 34 91 378 98 30 | Polska Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 |
France Gilead Sciences Tél: + 33 (0) 1 46 09 41 00 | Portugal Gilead Sciences, Lda. Tel: + 351 21 7928790 |
Hrvatska Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 | România Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Ireland Gilead Sciences Ireland UC Tel: + 353 (0) 214 825 999 | Slovenija Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Ísland Gilead Sciences Sweden AB Sími: + 46 (0) 8 5057 1849 | Slovenská republika Gilead Sciences Slovakia s.r.o. Tel: + 421 232 121 210 |
Italia Gilead Sciences S.r.l. Tel: + 39 02 439201 | Suomi/Finland Gilead Sciences Sweden AB Puh/Tel: + 46 (0) 8 5057 1849 |
Κ?προς Gilead Sciences Ελλ?ς Μ.ΕΠΕ. Τηλ: + 30 210 8930 100 | Sverige Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 |
Latvija Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 | United Kingdom Gilead Sciences Ltd. Tel: + 44 (0) 8000 113 700 |
Date of Last Revision of this Leaflet:{MM/YYYY}
Detailed information on this medication is available on the European Medicines Agency website: http://www.ema.europa.eu.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for VIREAD 245 mg FILM-COATED TABLETS – subject to medical assessment and local rules.